title: Clinical features and outcome of patients with HIV-negative multicentric Castleman's disease treated with combination chemotherapy: a report on 10 patients.
abstract: To investigate the clinical characteristics and outcome of patients with HIV-negative multicentric Castleman's disease (MCD) treated exclusively with combination chemotherapy, and review literature to improve the diagnosis and management of this disease. A retrospective study was performed on the medical records of 10 patients with HIV-negative MCD treated exclusively with combination chemotherapy at one medical institution from May 2004 to April 2012. And relevant clinical, pathological, radiographic, and laboratory data were examined in order to evaluate treatment responses, with symptom onsets and survival period serving as the endpoints of the assessment. All patients have multifocal lymphadenopathy, and the associated system symptoms are found in 80 % of the cases. All patients were treated with lymphoma-based chemotherapy alone. The duration of follow-up ranged from 5 to 77 months for nine patients. Four patients were treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) alone: One was alive with no evidence of disease, and three were alive with disease. Three patients received cyclophosphamide, vincristine, and prednisone (COP) alone: One remained alive with disease, and two experienced recurrences and passed away. Two had only minimal response to COP and were switched to CHOP, and they were still alive with disease. MCD is a more progressive clinical entity, and long-term follow-up is necessary. CHOP chemotherapy may be an effective treatment option for patients with MCD, whereas when to start chemotherapy, how many cycles of chemotherapy required, and the role of combined radiotherapy remain to be further studied.
authors: Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, 440 Ji Yan Road, Jinan, China.
authors: Shou-Hui
authors: SH
authors: Zhu
authors: Yong-Hua
authors: YH
authors: Yu
authors: Yong
authors: Y
authors: Zhang
authors: Ju-Jie
authors: JJ
authors: Sun
authors: Da-Li
authors: DL
authors: Han
authors: Jia
authors: J
authors: Li
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005871:Castleman Disease / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006679:HIV Seropositivity; D006801:Humans; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D012189:Retrospective Studies; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
references: Intern Med. 2003 Feb;42(2):182-6
references: 12636239
references: Histopathology. 1994 May;24(5):437-43
references: 8088715
references: Cancer. 1956 Jul-Aug;9(4):822-30
references: 13356266
references: J Clin Exp Hematop. 2008 Nov;48(2):39-45
references: 19039195
references: J Nucl Med. 1997 Aug;38(8):1211-2
references: 9255152
references: Med Oncol. 2010 Dec;27(4):1171-8
references: 19937164
references: Rev Esp Med Nucl. 2007 Jan-Feb;26(1):40-5
references: 17286947
references: Rev Esp Med Nucl Imagen Mol. 2012 May-Jun;31(3):142-4
references: 22133346
references: Virchows Arch A Pathol Anat Histopathol. 1993;423(5):369-82
references: 8116226
references: Med Oncol. 2012 Jun;29(2):1109-13
references: 21472488
references: J Clin Invest. 2006 Mar;116(3):735-42
references: 16498502
references: Curr Opin Oncol. 2011 Sep;23(5):475-81
references: 21760504
references: Surgery. 1992 Nov;112(5):850-5
references: 1440235
references: Blood. 1999 Jun 15;93(12):4034-43
references: 10361100
references: Kidney Int. 2000 Dec;58(6):2390-9
references: 11115072
references: Cancer. 1979 Aug;44(2):457-62
references: 476562
references: Cancer. 1972 Mar;29(3):670-83
references: 4551306
references: Cancer. 1999 Feb 1;85(3):706-17
references: 10091744
references: Oncologist. 2011;16(9):1316-24
references: 21765191
references: Am J Clin Pathol. 1978 Jan;69(1):86-90
references: 619617
references: Am J Kidney Dis. 2004 Jan;43(1):E3-9
references: 14712466
references: J Pediatr Surg. 1995 May;30(5):745-7
references: 7623245
references: Radiat Oncol. 2010 Feb 02;5:7
references: 20122250
references: Am J Surg Pathol. 1997 Nov;21(11):1295-306
references: 9351567
references: Int J Radiat Oncol Biol Phys. 1978 Nov-Dec;4(11-12):1045-8
references: 102620
references: Curr Opin Hematol. 2007 Jul;14(4):354-9
references: 17534161
references: Acta Cytol. 2009 May-Jun;53(3):316-8
references: 19534275
references: Semin Oncol. 1993 Dec;20(6):636-47
references: 8296200
references: Cancer Treat Rev. 1995 Jul;21(4):291-310
references: 7585657
references: Blood. 2002 Apr 1;99(7):2331-6
references: 11895764
references: J Clin Oncol. 1985 Sep;3(9):1202-16
references: 4031967
references: Ann Intern Med. 1998 Apr 15;128(8):657-62
references: 9537940
references: Mayo Clin Proc. 1995 Oct;70(10):969-77
references: 7564550
references: Adv Anat Pathol. 2009 Jul;16(4):236-46
references: 19546611
references: Cancer. 2001 Aug 1;92(3):670-6
references: 11505414
references: Br J Haematol. 2005 Apr;129(1):3-17
references: 15801951
references: Int J STD AIDS. 2006 Jan;17(1):19-24; quiz 25
references: 16409673
references: Clin Adv Hematol Oncol. 2010 Jul;8(7):486-98
references: 20864917